Cargando…
A country-specific model of COVID-19 vaccination coverage needed for herd immunity in adult only or population wide vaccination programme
We present a country specific method to calculate the COVID-19 vaccination coverage needed for herd immunity by considering age structure, age group-specific contact patterns, relative infectivity and susceptibility of children to adults, vaccination effectiveness and seroprevalence prior to vaccina...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier B.V.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9119722/ https://www.ncbi.nlm.nih.gov/pubmed/35636311 http://dx.doi.org/10.1016/j.epidem.2022.100581 |
_version_ | 1784710752896024576 |
---|---|
author | Goh, Fang Ting Chew, Yi Zhen Tam, Clarence C. Yung, Chee Fu Clapham, Hannah |
author_facet | Goh, Fang Ting Chew, Yi Zhen Tam, Clarence C. Yung, Chee Fu Clapham, Hannah |
author_sort | Goh, Fang Ting |
collection | PubMed |
description | We present a country specific method to calculate the COVID-19 vaccination coverage needed for herd immunity by considering age structure, age group-specific contact patterns, relative infectivity and susceptibility of children to adults, vaccination effectiveness and seroprevalence prior to vaccination. We find that across all six countries, vaccination of adults age 60 and above has little impact on R(eff) and this is could be due to the smaller number of contacts between this age group and the rest of the population according to the contact matrices used. If R(0) is above 6, herd immunity by vaccine alone is unattainable for most countries either if vaccination is only available for adults or that vaccine effectiveness is lower at 65% against symptomatic infections. In this situation, additional control measures, booster shots, if they improve protection against infection, or the extension of vaccination to children, are required. For a highly transmissible variant with R(0) up to 8, herd immunity is possible for all countries and for all four scenarios of varying relative infectivity and susceptibility of children compared to adults, if vaccine effectiveness is very high at 95% against symptomatic infections and that high vaccination coverage is achieved for both adults and children. In addition, we show that the effective reproduction number will vary between countries even if the same proportion of the population is vaccinated, depending on the demographics, the contact rates and the previous pre-vaccination seroprevalence in the country. This therefore means that care must be taken in extrapolating population level impacts of certain vaccine coverages from one country to another. |
format | Online Article Text |
id | pubmed-9119722 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | The Authors. Published by Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91197222022-05-20 A country-specific model of COVID-19 vaccination coverage needed for herd immunity in adult only or population wide vaccination programme Goh, Fang Ting Chew, Yi Zhen Tam, Clarence C. Yung, Chee Fu Clapham, Hannah Epidemics Article We present a country specific method to calculate the COVID-19 vaccination coverage needed for herd immunity by considering age structure, age group-specific contact patterns, relative infectivity and susceptibility of children to adults, vaccination effectiveness and seroprevalence prior to vaccination. We find that across all six countries, vaccination of adults age 60 and above has little impact on R(eff) and this is could be due to the smaller number of contacts between this age group and the rest of the population according to the contact matrices used. If R(0) is above 6, herd immunity by vaccine alone is unattainable for most countries either if vaccination is only available for adults or that vaccine effectiveness is lower at 65% against symptomatic infections. In this situation, additional control measures, booster shots, if they improve protection against infection, or the extension of vaccination to children, are required. For a highly transmissible variant with R(0) up to 8, herd immunity is possible for all countries and for all four scenarios of varying relative infectivity and susceptibility of children compared to adults, if vaccine effectiveness is very high at 95% against symptomatic infections and that high vaccination coverage is achieved for both adults and children. In addition, we show that the effective reproduction number will vary between countries even if the same proportion of the population is vaccinated, depending on the demographics, the contact rates and the previous pre-vaccination seroprevalence in the country. This therefore means that care must be taken in extrapolating population level impacts of certain vaccine coverages from one country to another. The Authors. Published by Elsevier B.V. 2022-06 2022-05-20 /pmc/articles/PMC9119722/ /pubmed/35636311 http://dx.doi.org/10.1016/j.epidem.2022.100581 Text en © 2022 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Goh, Fang Ting Chew, Yi Zhen Tam, Clarence C. Yung, Chee Fu Clapham, Hannah A country-specific model of COVID-19 vaccination coverage needed for herd immunity in adult only or population wide vaccination programme |
title | A country-specific model of COVID-19 vaccination coverage needed for herd immunity in adult only or population wide vaccination programme |
title_full | A country-specific model of COVID-19 vaccination coverage needed for herd immunity in adult only or population wide vaccination programme |
title_fullStr | A country-specific model of COVID-19 vaccination coverage needed for herd immunity in adult only or population wide vaccination programme |
title_full_unstemmed | A country-specific model of COVID-19 vaccination coverage needed for herd immunity in adult only or population wide vaccination programme |
title_short | A country-specific model of COVID-19 vaccination coverage needed for herd immunity in adult only or population wide vaccination programme |
title_sort | country-specific model of covid-19 vaccination coverage needed for herd immunity in adult only or population wide vaccination programme |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9119722/ https://www.ncbi.nlm.nih.gov/pubmed/35636311 http://dx.doi.org/10.1016/j.epidem.2022.100581 |
work_keys_str_mv | AT gohfangting acountryspecificmodelofcovid19vaccinationcoverageneededforherdimmunityinadultonlyorpopulationwidevaccinationprogramme AT chewyizhen acountryspecificmodelofcovid19vaccinationcoverageneededforherdimmunityinadultonlyorpopulationwidevaccinationprogramme AT tamclarencec acountryspecificmodelofcovid19vaccinationcoverageneededforherdimmunityinadultonlyorpopulationwidevaccinationprogramme AT yungcheefu acountryspecificmodelofcovid19vaccinationcoverageneededforherdimmunityinadultonlyorpopulationwidevaccinationprogramme AT claphamhannah acountryspecificmodelofcovid19vaccinationcoverageneededforherdimmunityinadultonlyorpopulationwidevaccinationprogramme AT gohfangting countryspecificmodelofcovid19vaccinationcoverageneededforherdimmunityinadultonlyorpopulationwidevaccinationprogramme AT chewyizhen countryspecificmodelofcovid19vaccinationcoverageneededforherdimmunityinadultonlyorpopulationwidevaccinationprogramme AT tamclarencec countryspecificmodelofcovid19vaccinationcoverageneededforherdimmunityinadultonlyorpopulationwidevaccinationprogramme AT yungcheefu countryspecificmodelofcovid19vaccinationcoverageneededforherdimmunityinadultonlyorpopulationwidevaccinationprogramme AT claphamhannah countryspecificmodelofcovid19vaccinationcoverageneededforherdimmunityinadultonlyorpopulationwidevaccinationprogramme |